Latest Ratios: P/E Ratio 22.1x · EV/EBITDA 14.5x · ROE 11.8%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $353.9B | $300.4B | $469.9B | $493.8B | $503.7B | $480.0B | $337.0B | $284.0B | $244.9B | $217.2B | $154.9B |
| Enterprise Value | $407.9B | $354.4B | $521.5B | $535.8B | $537.9B | $504.7B | $363.5B | $313.7B | $270.6B | $236.9B | $177.5B |
| P/E Ratio → | 22.13 | 24.95 | 32.62 | 22.06 | 25.03 | 27.77 | 21.88 | 20.52 | 20.44 | 20.57 | 22.07 |
| P/S Ratio | 0.79 | 0.67 | 1.17 | 1.33 | 1.55 | 1.67 | 1.31 | 1.17 | 1.08 | 1.08 | 0.84 |
| P/B Ratio | 3.49 | 2.95 | 4.58 | 4.99 | 5.83 | 6.28 | 4.78 | 4.57 | 4.36 | 4.17 | 3.83 |
| P/FCF | 15.50 | 18.69 | 22.70 | 19.23 | 21.52 | 24.14 | 16.75 | 17.32 | 17.94 | 18.76 | 19.15 |
| P/OCF | 17.97 | 15.25 | 19.42 | 16.99 | 19.22 | 21.49 | 15.20 | 15.38 | 15.58 | 15.97 | 15.82 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.79 | 1.30 | 1.44 | 1.66 | 1.75 | 1.41 | 1.30 | 1.20 | 1.18 | 0.96 |
| EV / EBITDA | 14.47 | 15.20 | 14.33 | 14.75 | 16.90 | 18.64 | 14.37 | 14.00 | 13.68 | 13.57 | 11.84 |
| EV / EBIT | 21.51 | 18.95 | 21.75 | 16.56 | 18.92 | 21.05 | 16.23 | 15.93 | 15.60 | 15.57 | 13.72 |
| EV / FCF | — | 22.05 | 25.19 | 20.86 | 22.98 | 25.37 | 18.07 | 19.14 | 19.82 | 20.47 | 21.94 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.5% | 18.5% | 22.3% | 24.5% | 24.6% | 24.2% | 26.1% | 23.8% | 23.8% | 23.4% | 23.5% |
| Operating Margin | 4.2% | 4.2% | 8.1% | 8.7% | 8.8% | 8.3% | 8.7% | 8.1% | 7.7% | 7.6% | 7.0% |
| Net Profit Margin | 2.7% | 2.7% | 3.6% | 6.0% | 6.2% | 6.0% | 6.0% | 5.7% | 5.3% | 5.2% | 3.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.8% | 11.8% | 14.3% | 24.2% | 24.7% | 23.5% | 23.2% | 23.4% | 22.1% | 22.8% | 18.5% |
| ROA | 4.0% | 4.0% | 5.0% | 8.6% | 8.8% | 8.4% | 8.3% | 8.5% | 8.2% | 8.1% | 6.0% |
| ROIC | 9.2% | 9.2% | 16.4% | 18.6% | 19.2% | 18.1% | 17.8% | 17.0% | 16.9% | 16.9% | 16.2% |
| ROCE | 9.7% | 9.7% | 17.5% | 19.5% | 19.6% | 18.5% | 18.9% | 18.6% | 18.5% | 18.8% | 18.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.77 | 0.77 | 0.75 | 0.68 | 0.67 | 0.60 | 0.62 | 0.65 | 0.65 | 0.61 | 0.82 |
| Debt / EBITDA | 3.36 | 3.36 | 2.11 | 1.86 | 1.81 | 1.70 | 1.72 | 1.82 | 1.85 | 1.82 | 2.20 |
| Net Debt / Equity | — | 0.53 | 0.50 | 0.42 | 0.40 | 0.32 | 0.38 | 0.48 | 0.46 | 0.38 | 0.56 |
| Net Debt / EBITDA | 2.32 | 2.32 | 1.42 | 1.16 | 1.08 | 0.91 | 1.05 | 1.33 | 1.30 | 1.13 | 1.50 |
| Debt / FCF | — | 3.36 | 2.49 | 1.64 | 1.46 | 1.24 | 1.32 | 1.81 | 1.88 | 1.70 | 2.79 |
| Interest Coverage | 4.67 | 4.67 | 6.14 | 9.97 | 13.59 | 14.44 | 13.47 | 11.55 | 12.39 | 12.82 | 12.12 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.79 | 0.79 | 0.83 | 0.79 | 0.77 | 0.79 | 0.74 | 0.69 | 0.73 | 0.73 | 0.69 |
| Quick Ratio | 0.79 | 0.79 | 0.83 | 0.79 | 0.77 | 0.79 | 0.74 | 0.69 | 0.73 | 0.73 | 0.69 |
| Cash Ratio | 0.24 | 0.24 | 0.28 | 0.30 | 0.31 | 0.31 | 0.27 | 0.23 | 0.27 | 0.31 | 0.27 |
| Asset Turnover | — | 1.45 | 1.34 | 1.36 | 1.32 | 1.36 | 1.30 | 1.39 | 1.49 | 1.45 | 1.51 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.2% | 2.6% | 1.6% | 1.4% | 1.2% | 1.1% | 1.4% | 1.4% | 1.4% | 1.3% | 1.5% |
| Payout Ratio | 65.7% | 65.7% | 52.3% | 30.2% | 29.8% | 30.5% | 29.8% | 28.4% | 27.7% | 26.3% | 32.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.5% | 4.0% | 3.1% | 4.5% | 4.0% | 3.6% | 4.6% | 4.9% | 4.9% | 4.9% | 4.5% |
| FCF Yield | 6.5% | 5.4% | 4.4% | 5.2% | 4.6% | 4.1% | 6.0% | 5.8% | 5.6% | 5.3% | 5.2% |
| Buyback Yield | 1.6% | 1.8% | 1.9% | 1.6% | 1.4% | 1.0% | 1.3% | 1.9% | 1.8% | 0.7% | 0.8% |
| Total Shareholder Yield | 3.8% | 4.5% | 3.5% | 3.0% | 2.6% | 2.1% | 2.6% | 3.3% | 3.2% | 2.0% | 2.3% |
| Shares Outstanding | — | $910M | $929M | $938M | $950M | $956M | $961M | $966M | $983M | $985M | $968M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UNH stock.
UnitedHealth Group Incorporated's current P/E ratio is 22.1x. The historical average is 20.1x. This places it at the 66th percentile of its historical range.
UnitedHealth Group Incorporated's current EV/EBITDA is 14.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.6x.
UnitedHealth Group Incorporated's return on equity (ROE) is 11.8%. The historical average is 19.6%.
Based on historical data, UnitedHealth Group Incorporated is trading at a P/E of 22.1x. This is at the 66th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
UnitedHealth Group Incorporated's current dividend yield is 2.23% with a payout ratio of 65.7%.
UnitedHealth Group Incorporated has 18.5% gross margin and 4.2% operating margin.
UnitedHealth Group Incorporated's Debt/EBITDA ratio is 3.4x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Medicare Advantage cost and DOJ exposure
Metrics are mathematically derived from official filings.
Combined Ratio Swings Reveal Medical Cost Sensitivity
Based on UNH's reported quarterly ratios, the combined ratio ranged from 91.7% in 2025Q1 to 99.7% in 2025Q4 before settling at 94.2% in 2026Q3, leaving underwriting margins thin and highly sensitive to medical cost timing. Investors should note that any sustained move above 100% would erase underwriting profit entirely.
The swing from 91.7% to 99.7% over three quarters is driven largely by the loss ratio, which moved between 67.3% and 83.7%, suggesting that reserve estimates and utilization trends dominate the result rather than expense discipline. The 2026Q3 recovery to 94.2% is encouraging, but the expense ratio of 13.7% against 25.6% in 2026Q2 indicates the quarterly comparison is distorted by timing, so the run-rate underwriting margin remains unclear. Analysts should strip out prior-year development before treating the most recent quarter as representative.
ROE Recovery Remains Below Earlier Peak Levels
As reported in UNH's quarterly ratio data, ROE fell from 6.1% in 2026Q1 to 3.9% in 2026Q3, below the 5.9% to 6.1% range seen in 2024 and 2025, suggesting the return profile has not yet re-established its prior level. Based on reported figures, this decline coincides with a rising loss ratio.
ROE depends on underwriting profit plus investment income on float, and with the combined ratio near 94% the underwriting contribution is modest, leaving the return heavily reliant on float yield. The ROA of 1.3% against a 2026Q1 level of 2.0% points to compressed asset-level earnings rather than a leverage effect. The data suggests the return recovery is incomplete and that investors should monitor whether margin stabilization can lift ROE back toward the mid-single-digit range.
Premium Multiple Rests on Forward Earnings Recovery
Based on UNH's reported figures, the trailing P/E of 29.79 compares with a forward P/E of 19.13, and the P/B of 3.53 sits well above the sector peers ELV at 2.14 and HUM at 2.95. The gap implies the market is pricing a substantial earnings rebound.
A premium P/B combined with an ROE of 3.9% implies that the market expects returns to recover well above current levels, as a 3.5x book multiple is difficult to justify at single-digit ROE on a sustained basis. The compression from trailing to forward P/E reflects expected earnings recovery, which depends on the combined ratio holding near or below 94%. The conglomerate premium associated with the Optum segments may be supporting the multiple, but this rests on expectations that have not yet been demonstrated in the reported return data.
Debt-to-Equity Stable but Coverage Volatile
As reported in quarterly ratio data, UNH's debt-to-equity has held in a narrow 0.69 to 0.77 band, indicating stable financial leverage, while interest coverage swung from 9.49 in 2026Q1 to 0.26 in 2025Q4. Based on reported figures, the coverage volatility appears driven by earnings rather than debt levels.
Because D/E has remained steady while coverage collapsed in 2025Q4, the variance is best read as an earnings-denominator effect rather than a rise in borrowing cost. Premium-to-surplus leverage is not provided in the supplied data, so underwriting leverage against statutory capital cannot be confirmed. Investors should treat the balance sheet as adequate but note that low coverage in weaker quarters leaves limited cushion if utilization pressure persists.
P/B Overstates Value Given Float Dependence
The most commonly misapplied metric here is the trailing P/E of 29.79, which is distorted by reserve development and EPS swings from $6.85 to $0.01 across 2025. Based on reported figures, a P/B-anchored view better reflects the invested-asset base backing reserves.
Trailing P/E is distorted by prior-year reserve adjustments and the 2025Q4 near-zero earnings, making the multiple unreliable for judging a single period. Book value, which largely consists of invested assets supporting claims reserves, is a more stable anchor, though a P/B of 3.53 still implies investors expect strong future returns. Analysts should adjust earnings for reserve development and assess the DOJ Medicare Advantage exposure before relying on any single valuation multiple.